Company: Cision Vision, Inc.
Product/Model: Cision InVision 1.0
Classification/Type: US FDA Class 1 Phase contrast microscope;
GMDN: 65539 – Basic light microscope IVD
Cision Vision, Inc. is committed to achieving Net Zero greenhouse gas (GHG) emissions by 2050 in alignment with the UK Government’s Net Zero Strategy. We recognize our responsibility to contribute meaningfully to carbon reduction across the lifecycle of our products, including design, manufacturing, logistics, and service. Cision Vision, Inc. has completed the Evergreen Sustainable Supplier Assessment as part of our commitment to NHS sustainability goals. This assessment supports our internal alignment with the NHS Net Zero Supplier Roadmap and complements our Carbon Reduction Plan under PPN 06/21.
As a growing start-up, Cision Vision, Inc. has adopted 2025 as its baseline emissions year. Our initial footprint reflects early-stage manufacturing and distribution of the Cision InVision 1.0 medical device.
Baseline Emissions (2025):
This equates to an estimated 100 tCO₂e per device manufactured in the first year.
As this is the baseline year (2025), subsequent years’ data will be measured, monitored, and reported annually beginning in 2026 using the GHG Protocol Corporate Standard and supplier engagement tools.
Cision Vision, Inc. has set the following reduction goals:
To support our targets, the following projects have been initiated or planned:
This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance via Eco Sourcing Hub. It has been reviewed and signed off by the executive team of Cision Vision, Inc.